Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database.
Paola Maria CutroneoValentina IsgròValentina IentileMariacarmela SantarpiaGuido FerlazzoAndrea FontanaPaolo CarregaElena MatarangoloSimona BarnabaEdoardo SpinaGianluca TrifiròPublished in: British journal of clinical pharmacology (2020)
The most frequently reported safety issues were probably immune-related adverse events including general, gastrointestinal and respiratory disorders. Potentially emerging safety signals, such as ischaemic heart disease and cardiac failure, requiring further investigation were detected.